Home > Inhibitors & Agonists
Cat. No. Product name CAS No.
DCC5196 Tortuosamine

Natural psychoactive agent

DCC5197 Tos-gly-pro-arg-anba-ipa

Chromogenic peptide substrate for the rapid and specific photometric assay of recombinant hirudin (r-hirudin)

99700-50-2
DCC5198 Tosylaniline

Selective CA IX inhibitor

68-34-8
DCC5199 Toxt-in-8

Novel ToxT inhibitor, reducing Vibrio cholerae virulence in vivo and effectively inhibiting intestinal colonization in the infant mouse

DCC5200 Tp-008

Novel probe for activin receptor-like kinase (ALK4 and ALK5)

DCC5201 Tp-040

Novel inhibitor of O-GlcNAcase (OGA)

DCC5202 Tp-238 Hydrochloride

Novel probe for CECR2/BPTF bromodomains

2415263-05-5
DCC5203 Tpe-gal

First-in-class fluorescent drug delivery vesicle that can efficiently load both water-soluble and -insoluble anticancer drugs

DCC5204 Tph1-in-23a

Novel Peripheral Selective Tryptophan Hydroxylase 1 (TPH1) Inhibitor (IC 50 : 42nM) for Obesity and Fatty Liver Disease

DCC5205 Tpi1609-10

Inhibitor of tyrosine recombinases and Holliday junction-resolving enzymes; Antibacterial

1374458-85-1
DCC5206 Tpi-1917-49

Promising amyloid reducing agent by lowering the levels of Aβ.

1250849-11-6
DCC5207 Tpi-2659-17

Novel Specific Inhibitor of Type I Collagen Production in Fibrosis

DCC5208 Tpi-287

Novel taxane family member, reducing the brain metastatic colonization of breast cancer cells

849213-15-6
DCC5209 Tpl2-in-i

Novel tumour progression locus 2 (Tpl2) kinase inhibitor

915009-13-1
DCC5210 Tpmp-i-2

Enhancer of the cytotoxic effect of immunotoxins (ITs) which results in increased apoptosis in different cancer cells

102660-13-9
DCC5211 Tpp-cl2

Mitochondria-activatable luciferin (MAL-Probe)

DCC5212 Tp-s1-68

Novel Type-I Inhibitor of TIE-2

120187-04-4
DCC5213 Tracizoline

Potent I 2 -imidazoline receptor agonist

65248-90-0
DCC5214 Trans- Resveratrol-4’-sulfate Sodium Salt

Metabolite of Resveratrol

858127-12-5
DCC5215 Trans-abcd

Potent and selective NMDA agonist

117488-23-0
DCC5216 Trans-bopc1

Novel HuR binder, modulating HuR-RNA interactions

DCC5217 Trans-cbtbp

Novel KGA allosteric inhibitor

DCC5218 Trans-miyabenol C

Natural resveratrol trimer, acting as a protein kinase C inhibitor

109605-83-6
DCC5219 Trans-ocma

Natural specific inhibitor of γ-secretase, decreasing amyloid-beta levels without influencing cleavage of Notch, showing strong growth inhibitory effects on cancer cell lines and significant anti-complement activity, also acting as a PTP1B inhibitor

DCC5220 trans-resveratrol-3-o-glucuronide

Metabolite of Resveratrol

387372-17-0
DCC5221 trans-resveratrol-4'-o-glucuronide

Metabolite of Resveratrol

387372-20-5
DCC5222 Trantinterol

Novel Highly Selective β2-Adrenoceptor Agonist as an Oral Antiasthmatic Agent

611234-02-7
DCC5223 trapoxin B

Inhibitor of histone deacetylases

133155-90-5
DCC5224 Trc210258

Novel TGR5 agonist, reducing glycemic and dyslipidemic cardiovascular risk in animal models of diabesity

1431553-15-9
DCC5225 Trehalose-6-phosphate

Central sugar signal in plants, regulating sucrose use and allocation, underpinning crop growth and development

4484-88-2
DCC5226 Trenbolone Enanthate

Potent and long-acting derivative of the hormone Trenbolone

1629618-98-9
DCC5227 Triazophos

EC 3.1.1.7 (Acetylcholinesterase) inhibitor, acting as an insecticide, an acaricide, an agrochemical, and a nematicide

24017-47-8
DCC5228 Triciribine Phosphate

AKT Inhibitor, Enhancing Gemcitabine Activity in Pancreatic Cancer Cells

61966-08-3
DCC5229 Tridecyl 2-aminoacetate Hydrochloride

Potent NAE-hydrolyzing acid amidase (NAAA) inhibitor

94856-88-9
DCC5230 Trifluoperazine N-glucuronide

Metabolite of Trifluoperazine; Antidepressant and antipsychotic

165602-90-4
DCC5231 Trifluoroacetyl Lysine

Novel Bromodomain Binding Mimic of Lysine Acetylation

10009-20-8
DCC5232 Trigonellinamide

Metabolite of nicotinamide; Specific and potent inhibitor of NNMT, increasing histone methylation at H3K4 and methylated H3K4 occupancy at gene promoters

3106-60-3
DCC5233 Trimipramine

Antipsychotic and sedative agent as a potent antagonist of H1, 5-HT2A, and alpha1-adrenergic receptors

739-71-9
DCC5234 Tripartin

Specific inhibitor of the histone H3 lysine 9 demethylase KDM4 in HeLa cells.

1428962-73-5
DCC5235 Triplin

Copper ion chelator, causing the triple response phenotype by affecting copper ion transport in ethylene signaling from ATX1 to RAN1

1421584-86-2
DCC5236 Tritiozine

Novel anti-secretory and antiulcer agent for treatment of peptic ulcer disease and hypersecretory disorders

35619-65-9
DCC5237 Trk Inhibitor 7d

First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitor that Overcome Clinically Acquired Resistance

DCC5238 Trk-130

Novel opioid ligand for treatment of overactive bladder, acting as a μ-opioid receptor partial agonist

160359-68-2
DCC5239 Trka-in-1

Novel potent and selective inhibitor of Tropomyosin-related kinase A (TrkA)

DCC5240 trmd-in-51

First-in-class highly potent and selective inhibitor of TrmD (bacterial t-RNA-(N1G37) methyltransferase)

1456890-42-8
DCC5241 Tropanserin

Potent and selective 5-HT3 receptor antagonist

85181-40-4
DCC5242 Tropisetron

Serotonin 5-HT3 receptor antagonist

89565-68-4
DCC5243 Trovafloxacin

Fluroquinolone antibiotic, suppressing c-Myc transcription and myeloma growth, inhibiting pannexin-1 channels through which ATP is released as find-me signals in apoptotic Jurkat cells

147059-72-1
DCC5244 Trpa1 Agonist 2c

Novel Photosensitive and Photoswitchable TRPA1 Agonist, Optically Control Pain through Channel Desensitization

DCC5245 Trpa1-in-2

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

DCC5246 Trpa1-in-3

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

DCC5247 Trpa1-in-7

Novel potent and selective TRPA1 inhibitor, interacting with the N-terminal ankyrin repeat (ankyrinR) domain

DCC5248 Trpm2 Inhibitor A23

Novel selective inhibitor of the transient receptor potential melastatin 2 (TRPM2) channel, exhibiting TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showing neuroprotective activity in vitro, and significantly reducing ce

DCC5249 Trpm8-agonist-1

Novel agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel

DCC5250 Trpv6 Inhibitor Cis-22a

Novel selective TRPV6 inhibitor

1819366-84-1
DCC5251 Trxr1-in-b19

Novel TrxR1 inhibitor, selectively killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation

170950-29-5
DCC5252 Tryptanthrin

Natural DNA gyrase inhibitor, blocking leukotriene production, inhibiting P-glycoprotein, and showing anti-inflammatory and anti cancer activities

13220-57-0
DCC5253 Tryptorubin A

Natural Polycyclic Peptide from a Fungus-Derived Streptomycete

DCC5254 Tshr-nam-s37a

Novel highly selective negative allosteric modulator (NAM) of thyrotropin receptor (TSHR), binding at the ectodomain/TMD interface, between the converging helix, ECL1 and the IA, noncompetitively inhibiting PAM-C2-activation

DCC5255 Tslp-in-11a

Novel human thymic stromal lymphopoietin (TSLP) inhibitor

DCC5256 Ts-pysa

Novel isoform-selective inhibitor of the tumor-associated hCA IX and XII

DCC5257 Tsri265

Novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo

DCC5258 Tta-a8

Novel antagonist of T-type calcium channels

1146395-46-1
DCC5259 Ttk Protac 8e

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 1.7 nM

DCC5260 Ttk Protac 8j

First-in-class potent threonine tyrosine kinase (TTK) PROTAC, demonstrating strong TTK degradation in COLO-205 human colorectal cancer cells with DC 50 values of 3.1 nM

DCC5261 Ttr Stabilizer L6

Novel transthyretin (TTR) stabilizer, binding to the T4 binding pocket of TTR and preventing the dissociation of TTR to monomer

881290-53-5
DCC5262 Ttt-3002

FLT3 Kinase Inhibitor, Overcoming Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia

871037-95-5
DCC5263 Tu-514

LpxC substrate-analog inhibitor

273737-87-4
DCC5264 Tubulin-in-3n

Novel inhibitor of tubulin polymerization and caused HepG2 cells arrest in G2/M phase

DCC5265 Tubulin-in-iia

Novel potent tubulin polymerization inhibitor, forming stable interactions in the colchicine-binding site of tubulin, showing significant antiproliferative activities on a panel of tumor cell lines

DCC5266 Tug-1907

Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41)

DCC5267 Tug-2015

Novel allosteric modulator of free fatty acid receptor 3 (FFA3, previously GPR41)

DCC5268 Tulobuterol Hydrochloride

Long-acting beta2-adrenergic receptor agonist

56776-01-3
DCC5269 tumor Metastasis Blocker 5k

Novel Inhibitor of Metastatic Cancer Cell Migration and Invasion

1421376-31-9
DCC5270 Tunicamycin

Antibiotic, inhibiting the first step in the N-linked glycosylation in eukaryotes and inducing ER stress to activate the unfolded protein response (UPR)

11089-65-9
DCC5271 Turneroic Acid

Inhibitor of bacterial biofilm formation in Staphylococcus epidermidis

DCC5272 Tutuilamide A

Natural potent porcine pancreatic elastase (PPE) inhibitor

DCC5273 Txa1 Hydrochloride

Novel anticancer agent, affecting steroid biosynthesis, increasing RagD expression, and causing abnormal cellular cholesterol localization

DCC5274 Txa-709

Novel disruptor of the bacterial protein, FtsZ

DCC5275 Ty-51469

Chymase inhibitor, preventing the development and progression of non-alcoholic steatohepatitis, improving vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats

603987-59-3
DCC5276 Tyk2 Jh2-in-48

Novel highly potent and selective TYK2 JH2 inhibitor, providing robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model

DCC5277 Bll5 Maleate

First-in-class selective PRMT5 inhibitor, blocking EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected

880813-30-9
DCC5278 Tyr(po(nme2)2

Stable analog of phosphotyrosine (pTyr)

DCC5279 Tyrosinase Inhibitor Thio-2

Novel competitive inhibitor of tyrosinase enzyme

51146-75-9
DCC5280 U-101958 Maleate [224170-09-6]

Potent and selective dopamine D4 receptor antagonist

224170-09-6
DCC5281 Ua62784

Novel potent inhibitor of microtubule polymerization, binding directly to tubulin α/β heterodimers via the colchicine-binding site, perturbing mitotic spindles, delaying cells in mitosis and promotes apoptosis

313367-92-9
DCC5282 Uawj172

Novel potent and broad-spectrum antiviral agent against multiple strains of EV-D68, EV-A71, and CVB3, targeting the viral protein 2C

878922-36-2
DCC5283 Ubp512

Selective modulator of NMDA_receptor>NMDA receptors, potentiates responses at GluN1/GluN2A

1333112-78-9
DCC5284 Ubp618

Novel pan-inhibitor of GluN1/GluN2 receptors

1333110-86-3
DCC5285 Ubp646

Novel pan potentiator of GluN1/GluN2 receptors

1333213-35-6
DCC5286 Ubp684

Novel NMDAR positive allosteric modulator (PAM), robustly potentiating responses at all GluN1/GluN2 subtypes and at neuronal NMDARs

1357838-47-1
DCC5287 Ubtr008295a

Novel Antagonist of the USP5 Zinc Finger Ubiquitin-Binding Domain (USP5 ZnF-UBD)

6947-81-5
DCC5288 Ucb-11056

Modulator of cyclic AMP generation, amplifing induced cyclic AMP formation in rat brain tissue; Nootropic

127390-77-6
DCC5289 ucb30889

Potent ligand of synaptic vesicle protein 2A (SV2A)

650608-19-8
DCC5290 Ucb-6786

Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins

537018-21-6
DCC5291 Ucb-6876

Novel inhibitor of TNF signalling by stabilising an asymmetric form of the trimer, displaying a concentration-dependent response curve and selectivity over the TNFR1 extracellular domain and control proteins

637324-45-9
DCC5292 Ucb-fcrn-303

Novel allosteric modulator of neonatal Fc receptor (FcRn), binding to the extracellular domain of FcRn

DCC5293 uc-ddc-918013

Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3

313685-55-1
DCC5294 uc-ddc-931126

Selective competitive inhibitor of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3

736966-32-8
DCC5295 uc-ddc-966791

Competitive dual inhibitor of the hydrolysis FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate

485317-08-6
DCC5297 Uck2-in-135546734

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

DCC5298 Uck2-in-135546812

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

DCC5299 Uck2-in-20874830

Novel non-competitive UCK2 inhibitor, suppressing nucleoside salvage in cells both in the presence and absence of DHODH inhibitors

866842-71-9
DCC5300 ucl-1972

Histamine H3 Receptor Antagonist in Treatments of Cognition Disorders

220728-17-6
DCC5301 Ucl-2190 Hydrogen Maleate

The first potent nonimidazole H3 receptor antagonist (pKi=8.40)

DCC5302 Ucm-05194

Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), Showing Efficacy in Neuropathic Pain Amelioration

2400858-74-2
DCC5303 Ucm-1336

Novel potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor, improving survival in Ras-driven acute myeloid leukemia

1621535-90-7
DCC5304 Ucm710

Dual inhibitor of fatty acid amide hydrolase (FAAH) and α/β hydrolase domain 6 (ABHD6)

213738-77-3
DCC5305 Ucn-02

Stereoisomer of UCN-01, inhibiting protein kinase C with a slightly reduced potency than UCN-01

121569-61-7
DCC5306 Ucp1172

Novel dual inhibitor of dihydrofolate reductase (DHFR) and its functional analog, Rv2671

DCC5307 Ucph-102f

Fluorescent excitatory amino acid transporter subtype 1 (EAAT1) selective inhibitor

DCC5308 Ue2316

Potent and selective 11ß-HSD1 inhibitor, improving memory, including after intracerebroventricular drug administration to the central nervous system alone

1274933-58-2
DCC5309 Ufp512

Novel selective delta-opioid receptor agonist

480446-44-4
DCC5310 Ufr2709

Novel Nicotinic Acetylcholine Receptor Antagonist, Inhibiting Nicotine Reward and Decreases Anxiety and Decreasing Ethanol Intake in Alcohol-Preferring Rats

100609-40-3
DCC5311 Ugm-in-1

Novel inhibitor of UGM, impeding C. glutamicum growth

1027102-50-6
DCC5312 Ugm-in-2

Novel inhibitor of UGM, impeding C. glutamicum growth

1027102-49-3
DCC5313 Uic-94003

Novel potent human immunodeficiency virus type 1 (HIV-1) protease inhibito

206362-00-7
DCC5314 Uk-447841

Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)

465528-01-2
DCC5315 Uk-505749

Selective NEP inhibitor for treatment of the symptoms of Female sexual arousal disorder (FSAD)

DCC5316 Ukcp-110

Potent VMAT2 inhibitor

205443-03-4
DCC5317 Ul-766

Novel chemically stable fluorescent marker of the ureter

DCC5318 Um1024

Novel Vaccine Adjuvant for Mycobacterium tuberculosis

DCC5319 Umb103

Novel potent and selective dual PLK1 and BRD4 inhibitor, inducing apoptosis in pediatric tumor cell lines, leading to significant tumor regression

DCC5320 Umb298

Novel, Potent, and Selective CBP/P300 Inhibitor

DCC5321 Umc160

Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor

DCC5322 Um-c162

Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability

1799734-10-3
DCC5323 Unag Ligand

Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift

DCC5324 Unbs3157

Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway

868962-26-9
DCC5325 Unc0737 Featured

UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays.

1327276-39-0
DCC5326 Unc0965

Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates

DCC5327 Unc10112731

Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα)

DCC5328 Unc10112749a

Novel inhibitor of ROP18, inhibiting ROP18 within cells, and abrogating its effects on the host IRG pathway

DCC5329 Unc10245092

Novel Peptide Inhibitor for Calcium and Integrin Binding Protein 1 (CIB1)

DCC5330 Unc1653

Negative control for UNC1666 which is a dual Mer and Flt-3 tyrosine kinase inhibitor

DCC5331 Unc32a

Orally Active Adenosine A 1 Receptor Agonist

DCC5332 Unc4859

Novel Ligand of EEDm acting as an allosteric inhibitor of PRC2

DCC5333 Unc5114

Novel allosteric inhibitor of PRC2 catalytic activity

DCC5334 Unc5115

Novel allosteric inhibitor of PRC2 catalytic activity

DCC5335 Unc5635

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

DCC5336 Unc5636

Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT

DCC5337 Unc6212

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

DCC5338 Unc6349

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

DCC5339 Unc6641

Novel peptidomimetic antagonist of the PHF1 Tudor domain, binding both PHF1 Tudor domain and the related protein PHF19

DCC5340 Unc6864

Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain

DCC5341 Unc7040

Novel potent and selective PAM of CBX8, blocking H3K27me3 binding and enhancing CBX8 affinity for nucleic acids, evicting PRC1 from H3K27me3 targets triggering DLBCL cell differentiation

DCC5342 Unc9975

Novel β-arrestin-biased D2 receptor (D2R) agonist

1354030-19-5
DCC5343 Unipr500 Featured

Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent

DCC5344 Uodc14

The first bifunctional (chemoreactive and clickable) probe for Adenosine A1 and A3 Receptors

DCC5345 Upf-648

Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor

213400-34-1
DCC5346 Upg-100

Novel superagonist of the urotensin-II (UT) receptor

DCC5347 Upg-83

Novel Potent antagonist of the Urotensin-II (UT) Receptor

DCC5348 Upg-92

Novel superagonist of the urotensin-II (UT) receptor

DCC5349 Upg-95

Novel potent antagonist of the Urotensin-II (UT) receptor

DCC5350 Uproleselan

Novel E-Selectin antagonist, disrupting cell survival pathway activation, enhancing chemotherapy response and protecting from toxicity such as mucositis with improved survival in vivo

1983970-12-2
DCC5351 Ur-ak1

Novel Neuropeptide Y Y4 Receptor (Y4R) Antagonist (pK i values <7.57)

DCC5352 Ur-ak32

Novel Potent Neuropeptide Y Y4 Receptor (Y4R) Partial Agonist (pK i : 8.47)

DCC5353 Uralenol-3-methylether

Natural flavonoid from the leaves of Glycyrrhiza uralensis

150853-98-8
DCC5354 Ur-ap164

Novel Red-Emitting Fluorescent Dualsteric Probe for the Muscarinic Acetylcholine M2 Receptor

DCC5355 Urb524

Novel FAAH inhibitor

546141-07-5
DCC5356 Urb532

Potent, selective, and irreversible inhibitor of fatty acid amide hydrolase (FAAH)

195140-79-5
DCC5357 Ur-deba148

Novel potent partial agonist of histamine H4 receptors (H4R)

DCC5358 Ur-deba176

Novel potent partial agonist of histamine H4 receptors (H4R)

DCC5359 Ur-deba242

Py-5-Labeled Fluorescent Multipurpose Probe for Investigations on the Histamine H3 and H4 Receptors, acting as a partial agonist at the hH3R [pEC50 (reporter gene) 8.77] and as an inverse agonist/antagonist at the h/mH4Rs [pIC50 (reporter gene) 8.76/7.08;

DCC5360 Ur-kat479

Novel subtype selective histamine H2 receptor G protein-biased agonist

DCC5361 Ur-mb-158

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

DCC5362 Ur-mb-159

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

DCC5363 Ur-mk299

Novel NPY Y1 Receptor Antagonist

DCC5364 Ur-nr266

Novel fluorescent histamine H3 receptor ligand

DCC5365 Ur-po563

Novel H2 receptor agonist, functionally stimulating human cardiac H2 receptors in vitro and in vivo

DCC5366 Usp30i

Novel USP30 inhibitor, increasing Ub-TOM20 with an EC50 of 2.45 mM and inducing the maximal Ub-TOM20

DCC5367 uta1inh

Novel kidney urea transporter UT-A1 inhibitor

332144-37-3
DCC5368 uta1inh-b1

Novel

412937-56-5
DCC5369 V-06-018

Quorum sensing modulator as a LasR antagonist

299927-26-7
DCC5370 V-10367

Non-immunosuppressive immunophilins ligand, demonstrating enhanced neuroregeneration in the peripheral nervous system and CNS

DCC5371 V2 Inhibitor 4b

Novel Long Residence Time Superior Inhibitor of the Vasopressin V2 Receptor

DCC5372 V30-sp-8

Novel Mycobacterium Tuberculosis VapC-Activating Stapled Peptide, successfully penetrated Mycobacterium smegmatis cell membranes and exerted bactericidal activity at a minimum inhibitory concentration that inhibited 50% of the isolates (MIC50) < 6.25 μM

DCC5373 V4-015

Novel potent inhibitor of FGFR4 kinase activity

DCC5374 Va999024

Specific inhibitor of tissue Kallikrein>kallikrein

168825-65-8
DCC5375 Vabicaserin Hydrochloride

Selective 5-HT2C receptor full agonist

620948-34-7
DCC5376 Vadaclidine

Orally acting antinociceptive muscarinic agonist

141575-50-0
DCC5377 Valganciclovir

Prodrug of ganciclovir for treatment of cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant

175865-60-8
DCC5378 Validamine

Natural pseudo-aminosugar

32780-32-8
DCC5379 Valoluc

Novel prodrug of luciferin to mimic the transport and activation of valacyclovir, , being a robust and functional determinant of VACVase activity

DCC5380 Vandetanib Fumarate

Novel selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability

338992-00-0
DCC5381 Vanillylidenacetone

Novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice

22214-42-2
DCC5382 Varenicline Dihydrochloride

Partial α4ß2 nicotinic receptor agonist and α7 full agonist

866823-63-4
DCC5383 Variegatic Acid

Natural inhibitor of β-hexosaminidase release and tumor necrosis factor (TNF)-α secretion from rat basophilic leukemia (RBL 2H3) cells, with IC50 values of 10.4 μM and 16.8 μM, respectively, also inhibiting PKC β1 activity with an IC50 value of 36.2 μM

20988-30-1
DCC5384 Vb-201

Novel anticryptosporidial agent, acting as a toll-like receptor-2 (TLR2) antagonist

630112-41-3
DCC5385 Vb-703

Novel potent TLR‐4 activation inhibitor, attenuating the expression of fibrosis hallmark genes collagen, fibronectin (FN) and transforming growth factor β (TGF‐β) in kidneys and improved albumin/creatinine ratio with higher efficacy

DCC5386 Vbit-12

Novel potent inhibitor of VDAC1, directly interacting with purified VDAC1 and reducing its channel conductance

2089227-65-4
DCC5387 Vbit-3

Novel inhibitor of VDAC1 oligomerization and apoptosis

DCC5388 Vch-759

Novel non-nucleoside inhibitor of HCV RNA-dependent polymerase

1001913-13-8
DCC5389 Vchcaγ Inhibitor 40

Novel selective inhibitor of the γ-class enzyme of bacteria Vibrio cholerae A (VchCAγ)

DCC5390 Vd11-4-2

Novel potent and selective CA IX inhibitor

DCC5391 Vd12-09

Novel potent and selective CA IX inhibitor

DCC5392 Vdr Modulator C4

Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine

DCC5393 Vdr Modulator I5

Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine

DCC5394 Vdr Modulator I8

Novel nonsecosteroidal vitamin D receptor (VDR) modulator, enhancing pancreatic cancer therapy through remodeling of the tumor microenvironment by combination with gemcitabine

DCC5395 Ve-465

Novel Aurora kinase inhibitor

639089-73-9
DCC5396 Vegfr-in-v

Potent, Vascular Endothelial Growth Factor Receptor-​2 (VEGFR-2) Tyrosine Kinase Inhibitor

861874-34-2
<Prev1...178179180181182...191Next>